This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Espeland, M A Search for Related Content PubMed PubMed Citation Articles by Espeland, M A Social Bookmarking                   What's this?

Consent for genetics studies among clinical trial participants: findings from Action for Health in Diabetes (Look AHEAD)

K Dotson

S A Jaramillo

Department of Biostatistical Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, USA

S E Kahn

Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, VA Puget Sound Health Care System and University of Washington, Seattle, WA, USA

B Harrison

National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA

M Montez

The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

J P Foreyt

Behavioral Medicine Research Center, Baylor College of Medicine, Houston, TX, USA

B Montgomery

Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, VA Puget Sound Health Care System and University of Washington, Seattle, WA, USA

W C Knowler

Diabetes Epidemiology and Clinical Research Section, NIDDK, Phoenix, AZ, USA

Look AHEAD Research Group

Background Increasingly, genetic specimens are collected to expand the value of clinical trials through study of genetic effects on disease incidence, progression or response to interventions.

Purpose and methods We describe the experience obtaining IRB-approved DNA consent forms across the 19 institutions in the Action for Health in Diabetes (Look AHEAD), a clinical trial examining the effect of a lifestyle intervention for weight loss on the risk of serious cardiovascular events among individuals with type 2 diabetes. We document the rates participants provided consent for DNA research, identify participant characteristics associated with consent, and discuss implications for genetics research.

Results IRB approval to participate was obtained from 17 of 19 institutions. The overall rate of consent was 89.6% among the 15 institutions that had completed consenting at the time of our analysis, which was higher than reported for other types of cohort studies. Consent rates were associated with factors expected to be associated with weight loss and cardiovascular disease and to affect the distribution of candidate genes. Non-consent occurred more frequently among participants grouped as African-American, Hispanic, female, more highly educated or not dyslipidemic.

Limitations The generalizabilty of results is limited by the inclusion/exclusion criteria of the trial.

Conclusions Barriers to obtaining consent to participate in genetic studies may differ from other recruitment settings. Because of the potentially complex associations between personal characteristics related to adherence, outcomes and gene distributions, differential rates of consent may introduce biases in estimates of genetic relationships.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?